Aclarion reports 114% quarterly growth in scan volumes, raises $22M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- LCI Industries names interim CEO as Jason Lippert retires
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Aclarion Provides 2025 Update and 2026 Corporate Outlook
January 8, 2026 6:00 AM ESTQuarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3... More
